Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,350
+450 (1.81%)
Aug 14, 2025, 3:30 PM KST
20.71%
Market Cap 534.10B
Revenue (ttm) 20.89B
Net Income (ttm) -12.21B
Shares Out 21.07M
EPS (ttm) -952.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 198,706
Average Volume 162,402
Open 25,450
Previous Close 24,900
Day's Range 24,750 - 25,500
52-Week Range 15,950 - 42,250
Beta n/a
RSI 67.33
Earnings Date Aug 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 20
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.